Profitability
Weight: 25%
D-
30
- 5yr Avg ROIC -10.0%
- Operating Margin Trend +82.03 pp/yr
KNSA
Kiniksa Pharmaceuticals International, plc
AlphaQuality composite grade, weighted for platform & compounding fcf businesses.
⚠ 2 of the last 5 fiscal years showed negative net income — AlphaQuality will not grade above F for persistent unprofitability in a platform & compounding fcf business.
Grade overrides the 30.0 pillar composite — hard gates always win.
Capital Efficiency
Weight: 15%
F
0
- 5yr Avg ROE -7.1%
- 5yr Share-Count CAGR 5.0%
Growth Quality
Weight: 25%
A-
80
- Revenue-Growth Years (5) 4/5
Cash Generation
Weight: 20%
F
20
- 5yr FCF Margin -72.7%
- 5yr FCF/NI Conversion 0.47x
Balance Sheet
Weight: 10%
A+
100
- Net Debt / EBITDA -4.47x
- Interest Coverage (EBIT/Int) 30.00x
- Altman Z-Score 21.59
Stability
Weight: 5%
D+
42
- EPS Volatility (σ/μ) 1.06
- Negative-Revenue Years (5) 0/5
- Piotroski F-Score 5
Guru Flow
Curated superinvestor sentiment — not part of the AlphaQuality grade.3 of 3 gurus held; 1 added; 2 trimmed.
- Holders
- 3
- Avg Δ position
- -24.8%
- New buys
- 0
- Full exits
- 0
- Cooperman decreased -41%
- Greenblatt decreased -37%
- Wood increased +3%